Learn more about TANOVEA®-CA1, the first FDA conditionally-approved treatment for canine lymphoma through our webinar series!


Conditional Label Review (May 2, 2017)

Discussion of the mechanism of action, data, and key elements of the package insert
Douglas H. Thamm, VMD, DACVIM (Oncology)


Anticipating and Managing Adverse Effects (May 16, 2017)

In-depth look at key side effects and strategies to address them
Douglas H. Thamm, VMD, DACVIM (Oncology)


Clinical Studies and Ongoing Development (June 20, 2017)

Review of data and new studies since conditional approval
Kate Vickery, DVM, MS, DACVIM (Oncology)